AZN AstraZeneca Plc

AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 6012, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Company profile

Ticker

AZN

Exchange

NYSE

Website

astrazeneca.com

CEO

Pascal Soriot

Location

United Kingdom

Fiscal year end

Dec 31

Sector

Health Technology > Pharmaceuticals: Major

Industry (SEC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Allergan • Merck & Co. • Warner Chilcott • Teva Pharmaceutical Industries • Abbott Laboratories • Lilly Eli & Co • Bristol Myers Squibb • AbbVie ...

Former names

Zeneca Group PLC

SEC CIK

0000901832

AZN stock data

S&P 500

1M 1Y 2Y 5Y

Company financial data Financial data

Chart AZN financial data

Institutional ownership Q3 2019

AZN institutional ownership history Ownership history

0.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1	1	–
Opened positions	0	0	NaN%
Closed positions	0	1	-100.0%
Increased positions	1	1	–
Reduced positions	0	0	NaN%

13F shares	Current	Prev Q	Change
Total value	1.06M	968K	+9.9%
Total shares	11.74K	11.69K	+0.4%
Total puts	0	0	NaN%
Total calls	0	0	NaN%
Total put/call ratio	NaN	NaN	NaN%

Largest owners	Shares	Value	Change
Parametric Portfolio Associates	11.74K	$1.06M	+0.4%

Largest transactions	Shares	Bought/sold	Change
Parametric Portfolio Associates	11.74K	+44	+0.4%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Savient Pharmaceuticals • Celldex Therapeutics • Poniard Pharmaceuticals • Aventis • Sicor • Atrix Laboratories • Brickell Biotech • Spectrum Pharmaceuticals • Geovax Labs • Progenics Pharmaceuticals

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	6th grade Good

New words: Absent, absolute, Academy, Actuarial, Additionally, ADP, Aerosphere, affordability, aforementioned, anaesthetic, analogue, approach, Arabian, Aralez, Aspen, aspirin, assistance, asthma, AZN, BCise, began, Bevespi, biennial, biologic, Biovitrum, bolstered, Brazil, BRCAm, broad, broader, bronchodilator, buying, Bydureon, Byetta, Calquence, carcinoma, Circassia, classification, closure, commentary, competitor, composite, concentrated, conjunction, contrasting, cooperated, COPD, coverage, creditor, CRT, cut, CV, CVMD, CVRM, DAC, Daiichi, demonstrated, diminished, discontinued, Document, dual, Dualkir, duration, EBITDA, education, EGFR, EGFRm, eligibility, eligible, eliminating, emanating, encouraging, endocrine, enzyme, eosinophilic, epidermal, estimate, exceed, exceeding, expiry, exposure, extension, FALCON, false, Fasenra, Faslodex, faster, fell, felt, finalised, Fluenz, Food, France, freeze, grow, growing, hemisphere, highlighting, illustrated, inappropriately, inflammatory, influenza, inhaled, insolvency, Instance, insulin, intensity, IR, Japanese, Kemp, kinase, label, LAMA, legacy, lengthening, Linkbase, linked, Luye, MACE, matured, maximise, MCL, Medicaid, met, metoprolol, mitigated, Movantik, moved, National, nature, nebulisation, necessity, negative, negotiation, NMPA, notable, NRDL, objection, Ono, opportunity, originally, outweighed, overwhelming, PARP, passage, patient, payer, penetration, pharmacy, pilot, placebo, POLO, poly, polymerase, population, predominantly, prevailing, prioritisation, produce, promising, promote, proof, proprietary, published, qui, realized, recede, reclassified, recognition, Recordati, reimbursement, relief, renewed, resource, restriction, retranslation, ribose, rolled, round, Russia, Sankyo, Saudi, Schema, seal, Seloken, shift, Signatory, situation, slowly, Sobi, SoC, stabilised, statin, statistically, statute, strength, study, successful, succinate, symbol, Taxonomy, terminated, track, trend, Trustee, Tudorza, tyrosine, underlined, underlining, underpinned, undertaken, underway, Unfavourable, unrecognised, unsecured, uptake, usage, utilisation, utilised, Valuation, Venezuela, voluntary, weakened, welfare, Western, withdrew, XBRL, Zavicefta, Zomig

Removed: ADS, AG, arm, Astra, California, call, cardiac, closing, created, death, defending, Delaware, Director, distributed, Dow, failure, family, heart, infringement, Jersey, KB, KBI, litigation, LSE, manufacture, Master, Merck, middle, pending, put, ratio, relationship, research, retroactively, Room, settlement, SSE, Stockholm, Street, ultimate, USA, view

From filing 20-F 2018 FY